Director David Lucchino resigns; Katharine Knobil appointed to board
Korro Bio, Inc.
David Lucchino resigned from board effective Aug 26, 2024; no disagreement with management or board.
Lucchino signed consulting agreement: $9k/quarter through 2026 annual meeting, then $2k/quarter through 2027; option grant (~$150k, capped 8k shares) at 2025 meeting, vesting at 2026 meeting.
Board reduced size from 7 to 6, then increased to 7 to appoint Katharine Knobil, M.D. as Class III director; also appointed to Compensation Committee.
Dr. Knobil will serve until 2025 annual meeting; receives standard non-employee director compensation and indemnification.
On August 26, 2024, David L. Lucchino, a member of our Board of Directors, or the Board, notified us that he resigned from the Board, effective immediately.
and then increased the number of directors from six to seven to create a vacancy in Class III and then appointed Katharine Knobil, M.D. to fill the newly created vacancy on the Board in Class III effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
David L. Lucchino resigned as Director at Korro Bio, Inc..
Action
resigned
Role
Director
Exact text from the filing
On August 26, 2024, David L. Lucchino, a member of our Board of Directors, or the Board, notified us that he resigned from the Board, effective immediately.
Katharine Knobil, M.D. was appointed as Director at Korro Bio, Inc..
Action
appointed
Role
Director
Exact text from the filing
and then increased the number of directors from six to seven to create a vacancy in Class III and then appointed Katharine Knobil, M.D. to fill the newly created vacancy on the Board in Class III effective immediately.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.